See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Pembrolizumab/Axitinib Improves Survival vs Responses in Advanced RCC

Summary by cancernetwork.com
The biomarker analysis in CHECKMATE-426 showed that pembrolizumab plus sunitinib therapy is associated with positive outcomes with angiogenesis in RCC.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

cancernetwork.comcancernetwork.com

Pembrolizumab/Axitinib Improves Survival vs Responses in Advanced RCC

The biomarker analysis in CHECKMATE-426 showed that pembrolizumab plus sunitinib therapy is associated with positive outcomes with angiogenesis in RCC.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

cancernetwork.com broke the news in on Friday, August 1, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal